Abbott and Enanta Pharmaceuticals announced today that the companies have signed a worldwide deal to develop and commercialize hepatitis C virus NS3 and NS3/4A protease inhibitors. Enanta has discovered several HCV protease inhibitors that have demonstrated efficacy and pharmacokinetic profiles in pre-clinical studies. Upon closing, Enanta will receive an up-front payment of $57 million, which includes a cash payment and an equity investment. It also stands to receive up to $250 million in milestone payments.
- see the release on the pact
Abbott to buy Kos for $3.7B. Report